An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Study found that the current use of Pharmalgen® venom immunotherapy in clinical practice in the NHS appears to be based on limited and poor-quality clinical effectiveness research. Pharmalgen® may be cost-effective for a subgroup of patients at high risk of future stings and a subgroup in whom Pharmalgen® improves quality of life owing to reduced anxiety.
1 Liverpool Reviews and Implementation Group, Liverpool, UK
2 Department of Paediatrics, Paediatric Allergy, Imperial College London, London, UK
3 Coldingham-Economics Consultancy, Coldingham, UK
4 Royal Liverpool University Hospital, Liverpool, UK
5 Department of Paediatrics, Imperial College London/NIHR Comprehensive Biomedical Research Centre, Imperial College Healthcare NHS Trust, London, UK
* Corresponding author Email: r.dickson@liv.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document